[Susceptibility of clinical strains of gram-negative rods to selected beta-lactam antibiotics]. 1997

A Rokosz, and A Sawicka-Grzelak
Zakład Bakteriologii Klinicznej AM w Warszawie.

The aim of the study was to determine the activity of four beta-lactam antibiotics against nosocomial strains of gram-negative bacilli. Two antibiotics combined with beta-lactamase inhibitors: timentin (TIC/CLAV) and tazocin (PIP/TZB) and two carbapenems: imipenem and meropenem were applied. The clinical strains were isolated from patients hospitalized in the following wards: surgery and intensive care unit of State Clinical Hospital No 1 in Warsaw. The strains were identified in the automatic ATB system using ID 32 E and ID 32 GN strips. The susceptibility of isolates to antibacterial agents was determined in the automatic ATB system using ATB G- and ATB PSE strips. The susceptibility of the strains to imipenem, meropenem, timentin and tazocin was tested by disc-diffusion method. 157 strains of gram-negative bacilli were cultured. 100 strains were isolated from patients hospitalized in surgical ward and 57 strains from patients hospitalized in ICU. Nonfermenting rods dominated among isolated strains-91. The results obtained indicate that multiresistant gram-negative rods causing serious therapeutic problems are often isolated from clinical specimens. The contribution of nonfermenting rods, especially Pseudomonas spp. and Acinetobacter spp. to the etiology of infections in hospitalized patients has increased. Infections caused by these strains are difficult to cure. Tazocin and carbapenems (imipenem and meropenem) are highly active in vitro against the examined strains of gram-negative bacilli.

UI MeSH Term Description Entries
D008826 Microbial Sensitivity Tests Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses). Bacterial Sensitivity Tests,Drug Sensitivity Assay, Microbial,Minimum Inhibitory Concentration,Antibacterial Susceptibility Breakpoint Determination,Antibiogram,Antimicrobial Susceptibility Breakpoint Determination,Bacterial Sensitivity Test,Breakpoint Determination, Antibacterial Susceptibility,Breakpoint Determination, Antimicrobial Susceptibility,Fungal Drug Sensitivity Tests,Fungus Drug Sensitivity Tests,Sensitivity Test, Bacterial,Sensitivity Tests, Bacterial,Test, Bacterial Sensitivity,Tests, Bacterial Sensitivity,Viral Drug Sensitivity Tests,Virus Drug Sensitivity Tests,Antibiograms,Concentration, Minimum Inhibitory,Concentrations, Minimum Inhibitory,Inhibitory Concentration, Minimum,Inhibitory Concentrations, Minimum,Microbial Sensitivity Test,Minimum Inhibitory Concentrations,Sensitivity Test, Microbial,Sensitivity Tests, Microbial,Test, Microbial Sensitivity,Tests, Microbial Sensitivity
D003428 Cross Infection Any infection which a patient contracts in a health-care institution. Hospital Infections,Nosocomial Infections,Health Care Associated Infection,Health Care Associated Infections,Healthcare Associated Infections,Infection, Cross,Infections, Hospital,Infections, Nosocomial,Cross Infections,Healthcare Associated Infection,Hospital Infection,Infection, Healthcare Associated,Infection, Hospital,Infection, Nosocomial,Infections, Cross,Infections, Healthcare Associated,Nosocomial Infection
D006090 Gram-Negative Bacteria Bacteria which lose crystal violet stain but are stained pink when treated by Gram's method. Gram Negative Bacteria
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000900 Anti-Bacterial Agents Substances that inhibit the growth or reproduction of BACTERIA. Anti-Bacterial Agent,Anti-Bacterial Compound,Anti-Mycobacterial Agent,Antibacterial Agent,Antibiotics,Antimycobacterial Agent,Bacteriocidal Agent,Bacteriocide,Anti-Bacterial Compounds,Anti-Mycobacterial Agents,Antibacterial Agents,Antibiotic,Antimycobacterial Agents,Bacteriocidal Agents,Bacteriocides,Agent, Anti-Bacterial,Agent, Anti-Mycobacterial,Agent, Antibacterial,Agent, Antimycobacterial,Agent, Bacteriocidal,Agents, Anti-Bacterial,Agents, Anti-Mycobacterial,Agents, Antibacterial,Agents, Antimycobacterial,Agents, Bacteriocidal,Anti Bacterial Agent,Anti Bacterial Agents,Anti Bacterial Compound,Anti Bacterial Compounds,Anti Mycobacterial Agent,Anti Mycobacterial Agents,Compound, Anti-Bacterial,Compounds, Anti-Bacterial
D013045 Species Specificity The restriction of a characteristic behavior, anatomical structure or physical system, such as immune response; metabolic response, or gene or gene variant to the members of one species. It refers to that property which differentiates one species from another but it is also used for phylogenetic levels higher or lower than the species. Species Specificities,Specificities, Species,Specificity, Species
D047090 beta-Lactams Four-membered cyclic AMIDES, best known for the PENICILLINS based on a bicyclo-thiazolidine, as well as the CEPHALOSPORINS based on a bicyclo-thiazine, and including monocyclic MONOBACTAMS. The BETA-LACTAMASES hydrolyze the beta lactam ring, accounting for BETA-LACTAM RESISTANCE of infective bacteria. beta-Lactam,4-Thia-1-Azabicyclo(3.2.0)Heptanes,4-Thia-1-Azabicyclo(4.2.0)Octanes,beta Lactam,beta Lactams

Related Publications

A Rokosz, and A Sawicka-Grzelak
January 1999, Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego,
A Rokosz, and A Sawicka-Grzelak
January 1985, Chemotherapy,
A Rokosz, and A Sawicka-Grzelak
April 1985, Zentralblatt fur Bakteriologie, Mikrobiologie, und Hygiene. Series A, Medical microbiology, infectious diseases, virology, parasitology,
A Rokosz, and A Sawicka-Grzelak
January 1989, Chemotherapy,
A Rokosz, and A Sawicka-Grzelak
November 1981, The Journal of antimicrobial chemotherapy,
A Rokosz, and A Sawicka-Grzelak
December 1987, Polski tygodnik lekarski (Warsaw, Poland : 1960),
A Rokosz, and A Sawicka-Grzelak
January 1986, Annales de l'Institut Pasteur. Microbiologie,
A Rokosz, and A Sawicka-Grzelak
September 1985, The Journal of antimicrobial chemotherapy,
Copied contents to your clipboard!